New lab research from Oregon Health & Science University reveals more than one path toward super-immunity from COVID-19.
It finds that two forms of immunity — breakthrough infections following vaccination or natural infection followed by vaccination — provide roughly equal levels of enhanced immune protection. The study’s published online in the journal Science Immunology.
Co-senior author Fikadu Tafesse, Ph.D., says, “It makes no difference whether you get infected and then vaccinated, or if you get vaccinated and then a breakthrough infection.” The assistant professor of molecular microbiology and immunology in the OHSU School of Medicine adds, “In either case, you will get a really, really robust immune response — amazingly high.”
The research follows a study O.H.S.U. published in December that described extremely high levels of immune response following breakthrough infections, so-called “super immunity.” That study was the first to use multiple live SARS-CoV-2 variants to measure cross-neutralization of blood serum from breakthrough cases.
The new study found that it doesn’t matter whether someone gets a breakthrough infection or gets vaccinated after a natural infection. In both cases, the immune response measured in blood serum revealed antibodies that were equally more abundant and at least 10 times more potent, than immunity generated by vaccination alone.
The study was done before the emergence of the highly transmissible omicron variant, but researchers expect the hybrid immune responses would be similar.
“The likelihood of getting breakthrough infections is high because there is so much virus around us right now,” Tafesse says. “But we position ourselves better by getting vaccinated. And if the virus comes, we’ll get a milder case and end up with this super immunity.”
Researchers recruited 104 OHSU employees who were vaccinated with the Pfizer vaccine. They divided them into three groups: 42 who were vaccinated with no infection, 31 who were vaccinated after an infection, and 31 who had breakthrough infections following vaccination. Controlling for age, sex and time from vaccination and infection, the researchers drew blood samples from each participant and exposed the samples to three variants of the live SARS-CoV-2 virus in a Biosafety Level 3 lab on OHSU’s Marquam Hill campus.
They found both of the groups with “hybrid immunity” generated greater levels of immunity compared with those who were vaccinated with no infection.
With the wildly contagious omicron variant now circulating across the globe, the new findings suggest each new breakthrough infection potentially brings the pandemic closer to the end.
“I would expect at this point many vaccinated people are going to wind up with breakthrough infections — and hence a form of hybrid immunity,” says senior co-author Dr. Bill Messer, assistant professor of molecular microbiology and immunology, and medicine.
Over time, the virus will run into an ever-expanding pool of human immunity.
OHSU scientists say they haven’t tested multiple rounds of natural infection, although many people will likely find themselves in that category, given that millions of people in the United States and around the world remain unvaccinated. With the spread of the highly contagious omicron variant, many unvaccinated people who were previously infected are likely to confront the virus again.
For that group, previous research shows a much more variable level of immune response than vaccination, Messer said.
“I can guarantee that such immunity will be variable, with some people getting equivalent immunity to vaccination, but most will not,” he said. “And there is no way, short of laboratory testing, to know who gets what immunity. Vaccination makes it much more likely to be assured of a good immune response.”
Senior co-author Dr. Marcel Curlin says, “Immunity from natural infection alone is variable. Some people produce a strong response and others do not. But vaccination combined with immunity from infection almost always provides very strong responses. These results, together with our previous work, point to a time when SARS-CoV-2 may become a mostly mild endemic infection like a seasonal respiratory tract infection, instead of a worldwide pandemic.”